Placebo for empasiprubart- solution for IV infusion

DRUG2 trials

Sponsors

Argenx

Conditions

Chronic inflammatory demyelinating polyneuropathy (CIDP)

Phase 3

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

RecruitingCTIS2024-520097-36-00

ArgenxChronic inflammatory demyelinating polyneuropathy (CIDP)

Start: 2026-01-07Target: 108Updated: 2025-12-09

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Not yet recruitingCTIS2025-520805-10-00

ArgenxChronic inflammatory demyelinating polyneuropathy (CIDP)

Target: 16Updated: 2026-02-11